P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS

• A. Kulasekararaj,
• R. Brodsky,
• M. Griffin,
• A. Kulagin,
• M. Ogawa,
• J. Wang,
• A. Mujeebuddin,
• J.-I. Nishimura,
• R. Peffault de Latour,
• J. Szer,
• J. W. Lee

Affiliations

A. Kulasekararaj

1 King’s College Hospital, National Institute of Health Research/Wellcome King’s Clinical Research Facility and King’s College London, London, United Kingdom

R. Brodsky

2 Division of Hematology, Johns Hopkins Medicine, Baltimore, United States of America

M. Griffin

3 St James Hospital, NHS Teaching Hospitals, Leeds, United Kingdom

A. Kulagin

4 RM Gorbacheva Research Institute, Pavlov University, St Petersburg, Russia

M. Ogawa

5 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America

J. Wang

5 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America

A. Mujeebuddin

5 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America

J.-I. Nishimura

6 Osaka University Graduate School of Medicine, Suita, Japan

R. Peffault de Latour

7 Hôpital Saint-Louis AP-HP, Paris, France

J. Szer

8 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia

J. W. Lee

9 Department of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea